{"id":51660,"date":"2025-12-20T21:54:53","date_gmt":"2025-12-20T13:54:53","guid":{"rendered":"https:\/\/flcube.com\/?p=51660"},"modified":"2025-12-20T21:54:54","modified_gmt":"2025-12-20T13:54:54","slug":"transthera-nda-accepted-for-tinengotinib-in-cholangiocarcinoma-after-fgfr-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51660","title":{"rendered":"TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor"},"content":{"rendered":"\n

TransThera Sciences (Nanjing), Inc.<\/strong> (HKG: 2617<\/a>) announced that China\u2019s National Medical Products Administration (NMPA)<\/strong> formally accepted its New Drug Application (NDA)<\/strong> for tinengotinib tablets<\/strong> for the treatment of advanced, metastatic, or unresectable cholangiocarcinoma (CCA)<\/strong> in adult patients who progressed after at least one systemic therapy and an FGFR inhibitor. The drug previously received Breakthrough Therapy Designation and Priority Review<\/strong> from NMPA.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
NDA Acceptance Date<\/strong><\/td>19\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Tinengotinib tablets<\/td><\/tr>
Indication<\/strong><\/td>Advanced, metastatic, or unresectable cholangiocarcinoma post-systemic therapy and FGFR inhibitor<\/td><\/tr>
Prior Designations<\/strong><\/td>Breakthrough Therapy Designation & Priority Review (NMPA)<\/td><\/tr>
Drug Class<\/strong><\/td>Oral, small-molecule multi-kinase inhibitor<\/td><\/tr>
Mechanism<\/strong><\/td>Targets FGFR\/VEGFR, JAK, and Aurora kinases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Competitive Landscape<\/h2>\n\n\n\n
Attribute<\/th>Tinengotinib<\/th>Competitive Context<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Multi-kinase inhibitor targeting FGFR\/VEGFR, JAK, and Aurora kinases<\/td>Broad spectrum vs. selective FGFR inhibitors<\/td><\/tr>
Administration<\/strong><\/td>Oral tablets (patient-convenient)<\/td>Differentiated from IV therapies<\/td><\/tr>
Indication Focus<\/strong><\/td>Cholangiocarcinoma post-FGFR inhibitor<\/td>Addresses high-unmet-need population<\/td><\/tr>
Development Status<\/strong><\/td>NDA accepted (Phase III completed)<\/td>Near-term commercialization potential<\/td><\/tr>
Innovation<\/strong><\/td>First multi-kinase inhibitor targeting FGFR\/VEGFR\/JAK\/Aurora for CCA<\/td>Novel combination of targets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China CCA Incidence<\/strong><\/td>~12,000-15,000 new cases annually<\/td>Rare but aggressive malignancy<\/td><\/tr>
FGFR-Altered CCA<\/strong><\/td>10-15% of CCA patients have FGFR2 fusions\/mutations<\/td>Eligible for FGFR inhibitors<\/td><\/tr>
Post-FGFR Inhibitor Market<\/strong><\/td>\u00a5500-800 million<\/strong> (\u2248 US$70-112M)<\/td>High unmet need after progression<\/td><\/tr>
Tinengotinib Peak Sales<\/strong><\/td>\u00a5300-500 million<\/strong> (\u2248 US$42-70M) by 2030<\/td>40-50% share of post-FGFR CCA segment<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Limited options; no approved therapy post-FGFR inhibitor<\/td>First potential therapy in this setting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n